Literature DB >> 10891407

Neutralization and enhancement of HIV-1 infection by sera from HIV-1 infected individuals who progress to disease at different rates.

P E Jolly1, H L Weiss.   

Abstract

We examined the neutralizing/enhancing activity in sera collected at an early and a later time point postinfection from 13 HIV-positive nonprogressors, 13 moderate progressors, and 13 rapid progressors to determine the relationship between neutralizing/enhancing activity and disease progression. Early sera from each group reduced virus replication at low dilutions (10(-1) to 10(-2)) when compared with negative sera. The reduction was statistically significant for moderate and rapid progressors at 10(-1) dilution (P = 0.02 and P = 0.02 respectively) but not for nonprogressors (P = 0.16). Late sera from nonprogressors and moderate progressors reduced virus replication at low dilution but late sera from rapid progressors lost neutralizing activity. These data suggest that an association exists between neutralizing activity in sera and nonprogression or slower progression to disease and that loss of neutralizing activity is associated with disease progression. At higher dilutions (10(-3) to 10(-6)), both early and late sera from each group increased virus replication over negative sera. The levels and frequency of enhancement were higher for sera from a subgroup of nonprogressors than a subgroup of rapid progressors who exhibited enhancement. This suggests that enhancement is not associated with disease progression. The neutralizing/enhancing activity observed in sera of these three groups of subjects suggest that enhancement levels may reflect the overall level of antibody response to HIV. The replication patterns observed for early and late sera from individuals in the different groups reflect changes in antibody activity that appear to be associated with protection or disease progression. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891407     DOI: 10.1006/viro.2000.0401

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Dynamic effects of antibody-dependent enhancement on the fitness of viruses.

Authors:  Derek A T Cummings; Ira B Schwartz; Lora Billings; Leah B Shaw; Donald S Burke
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-10       Impact factor: 11.205

2.  Specific history of heterologous virus infections determines anti-viral immunity and immunopathology in the lung.

Authors:  Hong D Chen; Armando E Fraire; Isabelle Joris; Raymond M Welsh; Liisa K Selin
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

3.  Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination.

Authors:  Donald N Forthal; Erin E Gabriel; Angela Wang; Gary Landucci; Tran B Phan
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

4.  Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection.

Authors:  Evelien M Bunnik; Linaida Pisas; Ad C van Nuenen; Hanneke Schuitemaker
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

5.  Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy.

Authors:  Gülşen Ozkaya Sahin; Emma J Bowles; Joe Parker; Hannes Uchtenhagen; Enas Sheik-Khalil; Stephen Taylor; Oliver G Pybus; Barbro Mäkitalo; Lilian Walther-Jallow; Mats Spångberg; Rigmor Thorstensson; Adnane Achour; Eva Maria Fenyö; Guillaume B E Stewart-Jones; Anna-Lena Spetz
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

6.  Maternal plasma viral load and neutralizing/enhancing antibodies in vertical transmission of HIV: a non-randomized prospective study.

Authors:  Paul Kamara; Loyda Melendez-Guerrero; Miguel Arroyo; Heidi Weiss; Pauline Jolly
Journal:  Virol J       Date:  2005-02-24       Impact factor: 4.099

7.  Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine.

Authors:  Fan Luo; Fan-Lu Liao; Hui Wang; Hong-Bin Tang; Zhan-Qiu Yang; Wei Hou
Journal:  Virol Sin       Date:  2018-03-14       Impact factor: 4.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.